Cargando…
Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan
Introduction: This manuscript reports on a pilot program focused on implementing pharmacogenetic testing within the framework of an employer-sponsored medical plan at University of Florida (UF) Health. The aim was to understand the challenges associated with program implementation and to gather insi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482099/ https://www.ncbi.nlm.nih.gov/pubmed/37680199 http://dx.doi.org/10.3389/fgene.2023.1249003 |
_version_ | 1785102113829814272 |
---|---|
author | Norris, Madeline Dalton, Rachel Alam, Benish Eddy, Elizabeth Nguyen, Khoa A. Cavallari, Larisa H. Sumfest, Jill Wiisanen, Kristin Cicali, Emily J. |
author_facet | Norris, Madeline Dalton, Rachel Alam, Benish Eddy, Elizabeth Nguyen, Khoa A. Cavallari, Larisa H. Sumfest, Jill Wiisanen, Kristin Cicali, Emily J. |
author_sort | Norris, Madeline |
collection | PubMed |
description | Introduction: This manuscript reports on a pilot program focused on implementing pharmacogenetic testing within the framework of an employer-sponsored medical plan at University of Florida (UF) Health. The aim was to understand the challenges associated with program implementation and to gather insights into patient attitudes towards PGx testing. Methods: The pilot program adopted a partially preemptive approach, targeting patients on current prescriptions for medications with relevant gene-drug associations. Patients were contacted via phone or through the MyChart system and offered pharmacogenetic testing with no additional direct costs. Results: Of 244 eligible patients, 110 agreed to participate. However, only 61 returned the mailed DNA collection kits. Among these, 89% had at least one potentially actionable genotype-based phenotype. Post-test follow-up revealed that while the majority viewed the process positively, 71% preferred a consultation with a pharmacogenetic specialist for better understanding of their results. Barriers to implementation ranged from fatigue with the healthcare system to a lack of understanding of the pharmacogenetic testing and concerns about privacy and potential misuse of genetic data. Conclusion: The findings underscore the need for clearer patient education on pharmacogenetic results and suggest the importance of the role of pharmacogenetic-trained pharmacists in delivering this education. They also highlight issues with relying on incomplete or inaccurate medication lists in patients’ electronic health record. The implementation revealed less obvious challenges, the understanding of which could be beneficial for the success of future preemptive pharmacogenetic implementation programs. The insights from the pilot program served to bridge the information gap between patients, providers, and pharmacogenetic -specialists, with the ultimate goal of improving patient care. |
format | Online Article Text |
id | pubmed-10482099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104820992023-09-07 Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan Norris, Madeline Dalton, Rachel Alam, Benish Eddy, Elizabeth Nguyen, Khoa A. Cavallari, Larisa H. Sumfest, Jill Wiisanen, Kristin Cicali, Emily J. Front Genet Genetics Introduction: This manuscript reports on a pilot program focused on implementing pharmacogenetic testing within the framework of an employer-sponsored medical plan at University of Florida (UF) Health. The aim was to understand the challenges associated with program implementation and to gather insights into patient attitudes towards PGx testing. Methods: The pilot program adopted a partially preemptive approach, targeting patients on current prescriptions for medications with relevant gene-drug associations. Patients were contacted via phone or through the MyChart system and offered pharmacogenetic testing with no additional direct costs. Results: Of 244 eligible patients, 110 agreed to participate. However, only 61 returned the mailed DNA collection kits. Among these, 89% had at least one potentially actionable genotype-based phenotype. Post-test follow-up revealed that while the majority viewed the process positively, 71% preferred a consultation with a pharmacogenetic specialist for better understanding of their results. Barriers to implementation ranged from fatigue with the healthcare system to a lack of understanding of the pharmacogenetic testing and concerns about privacy and potential misuse of genetic data. Conclusion: The findings underscore the need for clearer patient education on pharmacogenetic results and suggest the importance of the role of pharmacogenetic-trained pharmacists in delivering this education. They also highlight issues with relying on incomplete or inaccurate medication lists in patients’ electronic health record. The implementation revealed less obvious challenges, the understanding of which could be beneficial for the success of future preemptive pharmacogenetic implementation programs. The insights from the pilot program served to bridge the information gap between patients, providers, and pharmacogenetic -specialists, with the ultimate goal of improving patient care. Frontiers Media S.A. 2023-08-23 /pmc/articles/PMC10482099/ /pubmed/37680199 http://dx.doi.org/10.3389/fgene.2023.1249003 Text en Copyright © 2023 Norris, Dalton, Alam, Eddy, Nguyen, Cavallari, Sumfest, Wiisanen and Cicali. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Norris, Madeline Dalton, Rachel Alam, Benish Eddy, Elizabeth Nguyen, Khoa A. Cavallari, Larisa H. Sumfest, Jill Wiisanen, Kristin Cicali, Emily J. Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan |
title | Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan |
title_full | Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan |
title_fullStr | Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan |
title_full_unstemmed | Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan |
title_short | Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan |
title_sort | lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482099/ https://www.ncbi.nlm.nih.gov/pubmed/37680199 http://dx.doi.org/10.3389/fgene.2023.1249003 |
work_keys_str_mv | AT norrismadeline lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan AT daltonrachel lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan AT alambenish lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan AT eddyelizabeth lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan AT nguyenkhoaa lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan AT cavallarilarisah lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan AT sumfestjill lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan AT wiisanenkristin lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan AT cicaliemilyj lessonsfromclinicalimplementationofapreemptivepharmacogeneticpanelaspartofatestingpilotprogramwithanemployersponsoredmedicalplan |